Status:
COMPLETED
Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)
Lead Sponsor:
Stanford University
Collaborating Sponsors:
National Institutes of Health (NIH)
Conditions:
Kidney Cancer
Renal Cell Carcinoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
To assess whether changes in quantitative tumor perfusion parameters after 3 or 6 weeks of treatment, as measured by power Doppler ultrasound, can predict initial objective response, defined by curren...
Eligibility Criteria
Inclusion
- 18 years of age or older
- Pathology-confirmed diagnosis of Renal cell carcinoma (RCC)
- At least one tumor lesion greater than 1 cm in diameter, amenable to ultrasound imaging
- Written informed consent.
- Specific inclusion criteria:
- Arm 1: planned to be treated with combination of VEGFR2 tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI)
- Arm 2: planned to be treated with non-ICI therapy
Exclusion
- Any comorbid condition that, in the opinion of the treating provider or the Protocol Directors, compromises the participant's ability to participate in the study
Key Trial Info
Start Date :
December 5 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2023
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT04508725
Start Date
December 5 2020
End Date
November 30 2023
Last Update
July 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305